-
Company Profile
![]()
Exscientia Plc – Company Profile
Exscientia Plc (Exscientia) is an artificial intelligence-driven pharma tech company committed to discovering, designing, and developing drugs. The Company’s AI process is comprised of five elements, including Precision Target, Precision Design, Precision Experiment, Precision Medicine and Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Exscientia's advanced biophysical and x-ray techniques provide the experimental underpinnings for AI-design. The company gets high-precision information from viable patient tissue, screened...
Add to Basket -
Thematic Analysis
![]()
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...
-
Company Insights
![]()
Bayer AG – Digital Transformation Strategies
Bayer implemented a five-year global IT strategy to drive its digital business transformation by aligning itself to emerging technologies like cloud, IoT, and AI among others. The annual ICT spending of Bayer was estimated at $2.3 billion in 2022. A major share of this spending is earmarked for acquiring hardware, network and communications, and software from vendors. Bayer is a life science company engaged in research, development, manufacture, and supply of products in healthcare and agriculture. Total ICT Spending 2022...
-
Company Insights
![]()
Exscientia Ltd. – Tech Innovator Profile
Exscientia Ltd (Exscientia) is a company that automates the drug discovery and design process, leveraging artificial intelligence (AI) and big data technologies. Its AI-driven platform, Centaur AI, enables researchers to design numerous target specific compounds and pre-assess their potency, and Experiment AI provides successful experimental outcomes. This report provides insights into Exscientia Ltd., including an overview of the company and its product offering, detailed coverage of its business model and operations, information on its funding and partnerships, and biographies of...
-
Thematic Analysis
![]()
State of the Biopharmaceutical Industry 2023
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you - Examine the current attitudes of business leaders towards the emerging trends impacting the biopharmaceutical industry in the next 12 months. Understand the most impactful emerging technologies - Industry, Regulatory and Macroeconomic factors that are going to impact and dominate the industry throughout 2023. Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023, highlight top-selling drugs (2022 vs 2023), and overview...
-
Product Insights
![]()
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Products Market Report Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation...
-
Product Insights
![]()
Net Present Value Model: EXS-21546
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model EXS-21546 Drug Details EXS-21546 is under...
-
Product Insights
![]()
Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children. The Malaria pipeline market research report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and...
-
Product Insights
![]()
Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include an overall sensation of feeling unwell, cough, possibly bloody mucus, fatigue, shortness of breath, weight loss, and pain in the chest. The Tuberculosis pipeline market research report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive...
-
Product Insights
![]()
Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Schizophrenia include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia pipeline market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Company Insights
![]()
GlaxoSmithKline Plc – Digital Transformation Strategies
GlaxoSmithKline is harnessing the power of digital technologies such as AI, ML, and deep learning to accelerate the drug discovery and development process reduce the time and operational costs. The annual ICT spending of GlaxoSmithKline was estimated at $2.2 billion in 2021. A major share of this spending is earmarked for acquiring software, ICT services, and consulting from vendors. GlaxoSmithKline is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines, and consumer healthcare products. The GlaxoSmithKline digital...
-
Product Insights
![]()
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. The Alzheimer’s Disease Drugs in Development market research report provides an overview of the Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug...
-
Analyst Opinions
![]()
Smart Pharma – Technology brings Unprecedented Opportunities
Increased R&D costs, regulatory hurdles, and the emergence of new diseases are enforcing pharmaceutical companies to rethink their aging business models. The highly regulated pharma is slowly adopting emerging technologies to improve every aspect of the value chain, from drug discovery tIncreased R&D costs, regulatory hurdles, and the emergence of new diseases are enforcing pharmaceutical companies to rethink their aging business models. The highly regulated pharma is gradually adopting emerging technologies to improve every aspect of the value chain, from...
-
Case Studies
![]()
Use of Artificial Intelligence in Pharmaceutical Drug Development and Clinical Trials: Case Study
The pharmaceutical industry has a reputation as being risk averse to embracing new technologies and spent many years in “watch and wait” mode regarding artificial intelligence (AI). Compared to other industries, pharma has been slow to adopt AI, but there has been increased activity over the past few years. This case study provides an overview of how AI is currently being implemented by the pharmaceutical industry in drug discovery and clinical trials
-
Company Insights
![]()
Sanofi – Enterprise Tech Ecosystem Series
Sanofi launched Sanofi-Sunrise Initiative to cater to early stage innovations by investing in seed ideas and improve R&D together with venture capitalists. The initiative is headed by Sanofi’s Katherine Bowdish, Global R&D VP. In January 2019, Sanofi partnered with Munich based Startup Creasphere, the first digital health innovation hub in Europe. The company in association with startups in network aims to develop new and innovative healthcare solutions for its customers. In June 2019, Sanofi formed an alliance with Google to...
-
Company Insights
![]()
Bayer AG – Enterprise Tech Ecosystem Series
Bayer implemented a five-year global IT strategy to drive its digital business transformation by aligning itself to new technologies like cloud, IoT, and AI among others, and using them to create various digital platforms. Bayer is digitally transforming its internal operations to improve productivity and efficiency and have cost-effective functional areas. For example, it deployed a digital twin-based scheduling program at its pharma manufacturing site in Italy, bringing improvements in its quality-control lab, and transforming it into a smart factory....
-
Analyst Opinions
![]()
Artificial Intelligence – Transforming the future of Healthcare
Artificial intelligence describes the work processes of machines that would require intelligence, if performed by humans. The term ‘artificial intelligence’ refers to ‘investigating intelligent problem-solving behavior and creating intelligent computer systems’. The goal of AI systems is to develop systems capable of tackling complex problems in ways similar to human logic and reasoning. Insights, real world examples of innovation and implementation of disruptive technologies across the value chain
-
Company Insights
![]()
Company Profile: Exscientia Ltd
Exscientia Ltd (Exscientia) is a company that automates drug discovery and design process leveraging artificial intelligence and big data technologies.
-
Thematic Analysis
![]()
Digital Transformations and Emerging Technologies in the Healthcare Industry – 2019
Digital transformation generally refers to the utilization of emerging technologies to solve traditional problems. Instead of simply supporting traditional methods, digital transformation has the ability to lead to innovation in a business setting. The integration of a new technology across all business areas results in fundamental changes to its operations. This report provides an assessment on how the digital transformation is impacting healthcare industry and how it is expected to affect the sector in the near future.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.